Urotensin-II and cardiovascular remodeling

Peptides

Volumn 29, Issue 5, 2008, Pages 764-769

  Papadopoulos, Panayiota ^a   Bousette, Nicolas ^a   Giaid, Adel ^a  

^a MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

Animals; Atherosclerosis; Blood vessels; Congestive heart failure; Heart; Human

Indexed keywords

LOW DENSITY LIPOPROTEIN; MESSENGER RNA; SB 611812; UNCLASSIFIED DRUG; UROTENSIN II;

ARTICLE; CELL PROLIFERATION; CORONARY ARTERY; CORONARY ARTERY ATHEROSCLEROSIS; DRUG MECHANISM; ENDOTHELIUM CELL; FOAM CELL; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SMOOTH MUSCLE FIBER;

CARDIOVASCULAR SYSTEM; CORONARY ARTERY DISEASE; HUMANS; SULFONAMIDES; UROTENSINS; VENTRICULAR REMODELING;

ANIMALIA;

EID: 42049112735     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2007.09.012     Document Type: Article

References (50)

1. Ames R.S., Sarau H.M., Chambers J.K., Willette R.N., Aiyar N.V., Romanic A.M., Louden C.S., Foley J.J., Sauermelch C.F., Coatney R.W., Ao Z., Disa J., Holmes S.D., Stadel J.M., Martin J.D., Liu W.S., Glover G.I., Wilson S., McNulty D.E., Ellis C.E., Elshourbagy N.A., Shabon U., Trill J.J., Hay D.W., Ohlstein E.H., Bergsma D.J., and Douglas S.A. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 401 (1999) 282-286
2. Birker-Robaczewska M., Boukhadra C., Studer R., Mueller C., Binkert C., and Nayler O. The expression of urotensin II receptor (U2R) is up regulated by interferon-γ. J Recept Signal Transduct Res 23 (2003) 289-305
3. Bottrill F.E., Douglas S.A., Hiley C.R., and White R. Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries. Br J Pharmacol 130 (2000) 1865-1870
4. Bousette N., Hu F., Ohlstein E.H., Dhanak D., Douglas S.A., and Giaid A. Urotensin-II blockade with SB-611812 attenuates cardiac dysfunction in a rat model of coronary artery ligation. J Mol Cell Cardiol 41 (2006) 285-295
5. Bousette N., Ohlstein E.H., Dhanak D., Douglas S.A., and Giaid A. Urotensin-II receptor blockade reduces mortality and improves congestive heart failure. Circulation 112 (2005) II-453
6. Bousette N., Patel L., Douglas S.A., Ohlstein E.H., and Giaid A. Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta. Atherosclerosis 176 (2004) 117-123
7. Bousette N., Pottinger J., Al-Ramli W., Ohlstein E.H., Dhanak D., Douglas S.A., and Giaid A. Urotensin-II receptor blockade with SB-611812 attenuates cardiac remodeling in experimental ischemic heart disease. Peptides 27 (2006) 2919-2926
8. Brown R.D., Ambler S.K., Mitchell M.D., and Long C.S. The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. Annu Rev Pharmacol Toxicol 45 (2005) 657-687
9. Cohn J.N., Ferrari R., and Sharpe N. Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an international forum on cardiac remodeling. J Am Coll Cardiol 35 (2000) 569-582
10. Dimopoulos K., Salukhe T.V., Coats A.J., Mayet J., and Piepoli M. Metaanalyses of mortality and morbidity effects of an angiotensin receptor blocker in patients with chronic heart failure already receiving an ACE inhibitor (alone or with a beta-blocker). Int J Cardiol 93 (2004) 105-111
11. Dobaczewski M., Bujak M., Zymek P., Ren G., Entman M.L., and Frangogiannis N.G. Extracellular matrix remodeling in canine and mouse myocardial infarcts. Cell Tissue Res 324 (2006) 475-488
12. Douglas S.A., and Ohlstein E.H. Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease. Trends Cardiovasc Med 10 (2000) 229-237
13. Douglas S.A., and Ohlstein E.H. Urotensin receptors. In: Girdlestone D. (Ed). The IUPHAR compendium of receptor characterization and classification (2000), IUPHAR Media, London 365-372
14. Douglas S.A., Tayara L., Ohlstein E.H., Halawa N., and Giaid A. Congestive heart failure and expression of myocardial urotensin II. Lancet 359 (2002) 1990-1997
15. Frigerio M., and Roubina E. Drugs for left ventricular remodeling in heart failure. Am J Cardiol 96 (2005) 10L-18L
16. Galis Z.S., and Khatri J.J. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 90 (2002) 251-262
17. Gray G.A., Jones M.R., and Sharif I. Human urotensin II increases coronary perfusion pressure in the isolated rat heart: potentiation by nitric oxide synthase and cyclooxygenase inhibition. Life Sci 69 (2001) 175-180
18. Hadi H.A., Carr C.S., and Al Suwaidi J. Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome. Vasc Health Risk Manag 1 (2005) 183-198
19. Haluska B.A., Jeffriess L., Downey M., Carlier S.G., and Marwick T.H. Influence of cardiovascular risk factors on total arterial compliance. J Am Soc Echocardiogr 21 (2008) 123-128
20. Hassan G.S., Douglas S.A., Ohlstein E.H., and Giaid A. Expression of urotensin-II in human coronary atherosclerosis. Peptides 26 (2005) 2464-2472
21. Heringlake M., Kox T., Uzun O., Will B., Bahlmann L., Klaus S., Eleftheriadis S., Armbruster F.P., Franz N., and Kraatz E. The relationship between urotensin II plasma immunoreactivity and left ventricular filling pressures in coronary artery disease. Regul Pept 121 (2004) 129-136
22. Johns D.G., Ao Z., Naselsky D., Herold C.L., Maniscalco K., Sarov-Blat L., Steplewski K., Aiyar N., and Douglas S.A. Urotensin II-mediated cardiomyocytes hypertrophy: effect of receptor antagonist and role of inflammatory mediators. Naunyn Schmiedebergs Arch Pharmacol 370 (2004) 238-250
23. Johnson J.L. Matrix metalloproteinases: influence on smooth muscle cells and atherosclerotic plaque stability. Expert Rev Cardiovasc Ther 5 (2007) 265-282
24. Kakafika A.I., Liberopoulos E.N., and Mikhailidis D.P. Fibrinogen: a predictor of vascular disease. Curr Pharm Des 13 (2007) 1647-1659
25. Katugampola S.D., Kuc R.E., Maguire J.J., and Davenport A.P. G-protein-coupled receptors in human atherosclerosis: comparison of vasoconstrictors (endothelin and thromboxane) with recently de-orphanized (urotensin-II, apelin and ghrelin) receptors. Clin Sci (Lond) 103 (2002) 171S-175S
26. Kompa A.R., Thomas W.G., See F., Tzanidis A., Hannan R.D., and Krum H. Cardiovascular role of urotensin II: effect of chronic infusion in the rat. Peptides 25 (2004) 1783-1788
27. Libby P., and Lee R.T. Matrix matters. Circulation 102 (2000) 1874-1876
28. Lim M., Honisett S., Sparkes C.D., Komesaroff P., Kompa A., and Krum H. Differential effect of urotensin II on vascular tone in normal subjects and patients with chronic heart failure. Circulation 109 (2004) 1212-1214
29. Maguire J.J., and Davenport A.P. Is urotensin-II the new endothelin?. Br J Pharmacol 137 (2002) 579-588
30. Maguire J.J., Kuc R.E., Wiley K.E., Kleinz M.J., and Davenport A.P. Cellular distribution of immunoreactive urotensin-II in human tissues with evidence of increased expression in atherosclerosis and a greater constrictor response of small compared to large coronary arteries. Peptides 25 (2004) 1767-1774
31. Mahmoudi M., Curzen N., and Gallagher P.J. Atherogenesis: the role of inflammation and infection. Histopathology 50 (2007) 535-546
32. Meijs M.F., de Windt L.J., de Jonge N., Cramer M.J., Bots M.L., Mali W.P., and Doevendans P.A. Left ventricular hypertrophy: a shift in paradigm. Curr Med Chem 14 (2007) 157-171
33. Nothacker H.P., Wang Z., McNeill A.M., Saito Y., Merten S., O'Dowd B., Duckles S.P., and Civelli O. Identification of the natural ligand of an orphan G-protein-coupled receptor involved in the regulation of vasoconstriction. Nat Cell Biol 1 (1999) 383-385
34. Peng X., Yin H., Wang L.H., Chai S.B., Shu J.L., and Tang C.S. Content and activity of the focal adhesion kinase in cultured vascular smooth muscle cells enhanced by urotensin II. Sheng Li Xue Bao 52 (2000) 455-458
35. Rakowski E., Hassan G.S., Dhanak D., Ohlstein E.H., Douglas S.A., and Giaid A. A role for urotensin II in restenosis following balloon angioplasty: use of a selective UT receptor blocker. J Mol Cell Cardiol 39 (2005) 785-791
36. Richards A.M., Nicholls M.G., Lainchbury J.G., Fisher S., and Yandle T.G. Plasma urotensin II in heart failure. Lancet 360 (2002) 545-546
37. Russell F.D., Kearns P., Toth I., and Molenaar P. Urotensin-II converting enzyme activity of furin and trypsin in human cells in vitro. J Pharmacol Exp Ther 310 (2004) 209-214
38. Sauzeau V., Mellionnec E.L., Bertoglio J., Scalbert E., Pacaud P., and Loirand G. Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase. Circ Res 88 (2001) 1102-1104
39. Shi L., Ding W., Li D., Wang Z., Jiang H., Zhang J., and Tang C. Proliferation and anti-apoptotic effects of human urotensin II on human endothelial cells. Atherosclerosis 188 (2006) 260-264
40. Sleight P. Angiotensin II and trials of cardiovascular outcomes. Am J Cardiol 89 (2002) 11A-16A
41. Suzuki S., Wenyi Z., Hirai M., Hinokio Y., Suzuki C., Yamada T., Yoshizumi S., Suzuki M., Tanizawa Y., Matsutani A., and Oka Y. Genetic variations at urotensin II and urotensin II receptor genes and risk of type 2 diabetes mellitus in Japaneses. Peptides 25 (2004) 1803-1808
42. Totsune K., Takahashi K., Arihara Z., Sone M., Ito S., and Murakami O. Increased plasma urotensin II levels in patients with diabetes mellitus. Clin Sci (Lond) 104 (2003) 1-5
43. Totsune K., Takahashi K., Arihara Z., Sone M., Satoh F., Ito S., Kimura Y., Sasano H., and Murakami O. Role of urotensin II in patients on dialysis. Lancet 358 (2001) 810-811
44. Tzanidis A., Hannan R.D., Thomas W.G., et al. Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy. Circ Res 93 (2003) 246-253
45. Wang H., Mehta J.L., Chen K., Zhang X., and Li D. Human urotensin II modulates collagen synthesis and the expression of MMP-1 in human endothelial cells. J Cardiovasc Pharmacol 44 (2004) 577-581
46. Watanabe T., Kanome T., Miyazaki A., and Katagiri T. Human urotensin II as a link between hypertension and coronary artery disease. Hypertens Res 29 (2006) 375-387
47. Watanabe T., Suguro T., Kanome T., Sakamoto Y., Kodate S., Hagiwara T., Hongo S., Hirano T., Adachi M., and Miyazaki A. Human urotensin II accelerates foam cell formation in human monocyte derived macrophages. Hypertension 46 (2005) 738-744
48. Watanabe T., Pakala R., Katagiri T., and Benedict C.R. Synergistic effect of urotensin II with mildly oxidized LDL on DNA synthesis in vascular smooth muscle cells. Circulation 104 (2001) 16-18
49. Watanabe T., Takahashi K., Kanome T., Hongo S., Miyazaki A., Koba S., Katagiri T., Pakara R., and Benedict C.R. Human urotensin-II potentiates the mitogenic effect of mildly oxidized low-density lipoprotein on vascular smooth muscle cells: comparison with other vasoactive agents and hydrogen peroxide. Hypertens Res 29 (2006) 821-831
50. World Health Organization. Shaping the future. World Health Report 2003 (2003), WHO, Geneva